For instance, it has been verified that DLX6-AS1 hypermethylation could be a biomarker for sporadic colorectal cancer (CRC) progression and prognosis, whose high expression might indicate a shorter survival time in CRC patients (Lin et al., 2021). The gene discussed is DLX6; the disease is colorectal carcinoma.